Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions ...

Berenberg Bank analyst Sebastian Bray maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €22.00. The ...

Despite challenges in the Crop Science division, the strength of the Pharmaceuticals division and steady performance in Consumer Health are encouraging. Moreover, Bayer recently scored an ...

Dr. Marijn Dekkers, Bayer chief executive, 2010-2016 However, before we get into the history of this German pharmaceutical company, it’s a good idea to get your head around the different names ...

An avalanche of lawsuits filed against Bayer in Missouri is pitting the chemical maker against trial attorneys and cancer patients.

The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

Kepler Capital analyst Christian Faitz maintained a Hold rating on Bayer (0P6S – Research Report) on January 21 and set a price target of ...

The "Enterprise Tech Ecosystem Series: Bayer AG 2024" report has been added to ResearchAndMarkets.com's offering. The report provides insights into Bayer AG's tech activities, including its digital ...